PT1379224E - Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese - Google Patents

Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese Download PDF

Info

Publication number
PT1379224E
PT1379224E PT02721604T PT02721604T PT1379224E PT 1379224 E PT1379224 E PT 1379224E PT 02721604 T PT02721604 T PT 02721604T PT 02721604 T PT02721604 T PT 02721604T PT 1379224 E PT1379224 E PT 1379224E
Authority
PT
Portugal
Prior art keywords
carcinogenesis
treatment
receptor agonists
guanylate cyclase
tissue inflammation
Prior art date
Application number
PT02721604T
Other languages
English (en)
Inventor
Gary S Jacob
Kunwar Shailubhai
Gregory Nikiforovich
Original Assignee
Synergy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27559539&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1379224(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergy Pharmaceuticals Inc filed Critical Synergy Pharmaceuticals Inc
Publication of PT1379224E publication Critical patent/PT1379224E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT02721604T 2001-03-29 2002-03-28 Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese PT1379224E (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27943801P 2001-03-29 2001-03-29
US27943701P 2001-03-29 2001-03-29
US30085001P 2001-06-27 2001-06-27
US30380601P 2001-07-10 2001-07-10
US30735801P 2001-07-25 2001-07-25
US34864602P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
PT1379224E true PT1379224E (pt) 2009-10-22

Family

ID=27559539

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02721604T PT1379224E (pt) 2001-03-29 2002-03-28 Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese

Country Status (13)

Country Link
US (6) US7041786B2 (pt)
EP (4) EP2944648B1 (pt)
JP (3) JP4206272B2 (pt)
CN (5) CN102643333B (pt)
CA (3) CA2441970C (pt)
CY (1) CY1109504T1 (pt)
DE (1) DE60233040D1 (pt)
DK (1) DK1379224T4 (pt)
EA (1) EA006651B1 (pt)
ES (3) ES2330312T5 (pt)
HK (3) HK1136585A1 (pt)
PT (1) PT1379224E (pt)
WO (1) WO2002078683A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102643333B (zh) * 2001-03-29 2019-04-23 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
US20030232013A1 (en) * 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
CA2498581C (en) 2002-09-10 2019-03-19 National Jewish Medical And Research Center Thioredoxin composition and uses thereof for liquefaction of mucus or sputum
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1911763T1 (sl) * 2003-01-28 2010-11-30 Ironwood Pharmaceuticals Inc Sestavki za zdravljenje gastrointestinalnih motenj
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
WO2004071436A2 (en) * 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
EP2722060A3 (en) * 2004-06-25 2015-01-07 Thomas Jefferson University Guanylyl cyclase C ligands
WO2006102069A2 (en) * 2005-03-17 2006-09-28 Microbia, Inc. Methods and compositions for the treatment of hypertension and gastrointestinal disorders
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
WO2007101161A2 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007127487A2 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
CA2677399C (en) * 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
AU2008261102B2 (en) * 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009040047A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Therapeutic uses of ghrelin and combinations with stresscopin
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
EP2245171A2 (en) * 2008-02-01 2010-11-03 Chromocell Corporation Cell lines and methods for making and using them
EP2810951B1 (en) * 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149278A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递***在制备恶性肿瘤靶向治疗药物中的应用
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2011001620A (es) 2008-08-15 2011-03-25 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
EP2370087A4 (en) * 2008-12-02 2013-08-28 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
ES2608050T3 (es) * 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2013501071A (ja) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドを含む処方物
US20130045239A1 (en) 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
US8785600B2 (en) 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
PL2536742T3 (pl) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Leczenie zaburzeń żołądkowo-jelitowych
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP2682128B1 (en) * 2011-02-28 2017-11-08 National Cerebral and Cardiovascular Center Atrial natriuretic peptide or brain natriuretic peptide for use in preventing metastasis
CN107090016A (zh) 2011-03-01 2017-08-25 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2012149263A1 (en) * 2011-04-29 2012-11-01 Thomas Jefferson University Treatment and prevention of gastrointestinal syndrome
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
KR102046435B1 (ko) 2012-04-27 2019-11-19 밀레니엄 파머슈티컬스 인코퍼레이티드 항-gcc 항체 분자 및 gcc-표적화 치료법에 대한 감수성을 평가하기 위한 그 용도
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
RU2750211C2 (ru) 2013-03-15 2021-06-24 Орпро Терапьютикс, Инк. Продукт и способ для нормализации вязкости слизи
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014250956B2 (en) 2013-04-12 2019-04-04 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
EP3030252B1 (en) 2013-08-09 2018-11-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
FI4095130T3 (fi) 2013-10-18 2024-04-25 Novartis Ag Prostataspesifisen membraaniantigeenin (psma) leimattuja estäjiä, niiden käyttö kuvantamisaineina ja farmaseuttisia aineita eturauhassyövän hoitoon
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
CN113855791A (zh) 2014-05-02 2021-12-31 Qu生物制药公司 抗微生物免疫调节
CA3001727A1 (en) * 2015-11-18 2017-05-26 Synergy Pharmaceuticals, Inc. Compositions and method for the treatment and detection of colon cancer
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
CN107349417A (zh) * 2017-04-01 2017-11-17 南阳市中心医院 一种治疗食管鳞癌的ecm复合物以及其在制备治疗食管鳞癌的药物中的用途
EP3668533A4 (en) * 2017-08-18 2022-06-15 Thomas Jefferson University PROTECTION OF NORMAL TISSUE IN CANCER TREATMENT
WO2019215753A2 (en) 2018-05-07 2019-11-14 Mylan Laboratories Ltd Process for preparation of pure plecanatide
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE191145T1 (de) * 1987-01-23 2000-04-15 Gen Hospital Corp Hydralazin zur topischen behandlung von glaukom
US5106834A (en) * 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
AU3237193A (en) * 1991-12-11 1993-07-19 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
WO1994020856A1 (en) * 1993-03-09 1994-09-15 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CA2174928C (en) * 1993-10-26 2011-08-16 Scott A. Waldman Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
DE19744027A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
US6203513B1 (en) 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
EP1220872A1 (en) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
JP4088412B2 (ja) 2000-12-26 2008-05-21 トヨタ自動車株式会社 内燃機関の空燃比制御装置
WO2002062369A2 (en) * 2001-02-02 2002-08-15 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
WO2002074052A2 (en) 2001-03-16 2002-09-26 Glaukos Corporation Applicator and methods for placing a trabecular shunt for glaucoma treatment
CN102643333B (zh) 2001-03-29 2019-04-23 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
DE10292434D2 (de) * 2001-06-05 2004-07-29 Yueksel Savas Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
US6991726B2 (en) 2002-07-01 2006-01-31 Usfilter Corporation Filter having a media retaining plate
ES2320121T3 (es) 2002-07-19 2009-05-19 Yale University Dispositivo de drenaje uveoescleral.
SI1911763T1 (sl) 2003-01-28 2010-11-30 Ironwood Pharmaceuticals Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7073363B2 (en) 2003-05-20 2006-07-11 Schumag Ag Method for processing drawn material and drawn material production installation
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
TWI536429B (zh) 2004-11-18 2016-06-01 尼康股份有限公司 A position measuring method, a position control method, a measuring method, a loading method, an exposure method and an exposure apparatus, and a device manufacturing method
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
US20070101158A1 (en) 2005-10-28 2007-05-03 Elliott Robert C Security region in a non-volatile memory
WO2007101158A2 (en) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7692307B2 (en) 2006-12-08 2010-04-06 Intel Corporation Compliant structure for an electronic device, method of manufacturing same, and system containing same
WO2008106429A2 (en) 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
WO2008137318A1 (en) 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149278A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso

Also Published As

Publication number Publication date
CA2905585C (en) 2020-02-18
EP1379224A1 (en) 2004-01-14
JP2004532208A (ja) 2004-10-21
CN103638514A (zh) 2014-03-19
EP2944648A1 (en) 2015-11-18
EP2103624B1 (en) 2015-03-18
ES2330312T3 (es) 2009-12-09
EP2944648B1 (en) 2019-11-13
EA200301070A1 (ru) 2004-04-29
US20030073628A1 (en) 2003-04-17
CA2441970A1 (en) 2002-10-10
CN103641892A (zh) 2014-03-19
US8637451B2 (en) 2014-01-28
US20140121169A1 (en) 2014-05-01
EP2301952A3 (en) 2011-07-06
US20200325176A1 (en) 2020-10-15
CN103641892B (zh) 2015-06-17
CN102643333B (zh) 2019-04-23
US7041786B2 (en) 2006-05-09
CA2441970C (en) 2013-01-22
CA2795396C (en) 2015-11-17
US8114831B2 (en) 2012-02-14
CN102643333A (zh) 2012-08-22
ES2622468T3 (es) 2017-07-06
DK1379224T3 (da) 2009-11-09
EP2103624A1 (en) 2009-09-23
EA006651B1 (ru) 2006-02-24
EP1379224A4 (en) 2005-06-22
CA2795396A1 (en) 2002-10-10
DK1379224T4 (da) 2013-12-02
US20110212884A1 (en) 2011-09-01
EP2301952B1 (en) 2017-01-18
WO2002078683A1 (en) 2002-10-10
HK1136585A1 (en) 2010-07-02
EP1379224B2 (en) 2013-10-02
US7799897B2 (en) 2010-09-21
CA2905585A1 (en) 2002-10-10
ES2539132T3 (es) 2015-06-26
JP2009001582A (ja) 2009-01-08
EP1379224B1 (en) 2009-07-22
ES2330312T5 (es) 2014-01-31
CN1551760A (zh) 2004-12-01
JP2012149071A (ja) 2012-08-09
CN107029209A (zh) 2017-08-11
EP2301952A2 (en) 2011-03-30
CY1109504T1 (el) 2014-08-13
HK1217714A1 (zh) 2017-01-20
US20120142614A1 (en) 2012-06-07
HK1196135A1 (en) 2014-12-05
DE60233040D1 (de) 2009-09-03
US20060154868A1 (en) 2006-07-13
JP4206272B2 (ja) 2009-01-07

Similar Documents

Publication Publication Date Title
HK1217714A1 (zh) 治療組織炎症和癌變的鳥苷酸環化酶受體增效劑
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
PL367142A1 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
AU2002252527A1 (en) Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002321769A1 (en) Agonists and antagonists of cobesin for the treatment of metabolic disorders
AU2002313580A1 (en) Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002339685A1 (en) Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002321761A1 (en) Agonists and antagonists of disomet for the treatment of metabolic disorders
AU2002321766A1 (en) Agonists and antagonists of obesingen for the treatment of metabolic disorders
AU2002321770A1 (en) Agonists and antagonists of genceptin for the treatment of metabolic disorders
AU2002324297A1 (en) Agonists and antagonists of moxifin for the treatment of metabolic disorders
AU2002324300A1 (en) Agonists and antagonists of moceptin for the treatment of metabolic disorders
AU2002329001A1 (en) Agonists and antagonists of cylixin for the treatment of metabolic disorders
AU2002339681A1 (en) Agonists and antagonists of glucomin for the treatment of metabolic disorders
AU2002321767A1 (en) Tr xidatin agonists and antagonists treatment of metabolic disorders